GlaxoSmithKline Comes Short of Forecasts But Maintains Dividend -- Earnings Review
February 05 2020 - 9:58AM
Dow Jones News
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) reported full-year and
fourth-quarter results Wednesday. Here is what you need to
know:
SALES: The British pharmaceutical major reported sales of 8.90
billion pounds ($11.58 billion), up 8.6% on last year but behind
analyst forecasts of GBP9.03 billion as provided by FactSet.
ADJUSTED EPS: Adjusted earnings per share--a metric closely
watched by analysts that strips out one-off items--fell by 16% at
constant currency to 24.8 pence, below consensus forecasts of 30
pence.
WHAT WE WATCHED:
-DIVIDEND: Investors will be relieved to know that their
dividend in 2020 is safe. The company announced it was targeting
another year of unchanged payout at 80 pence a share.
However, the horizon beyond the consumer-health separation
remains unclear. Over-the-counter products might lack the high
margins of successful innovative drugs but they represent steady
cash flow with which to prop up the dividend. It remains to be seen
if it can be maintained once this is removed--and the company is
entirely dependent on the boom-and-bust of clinical breakthroughs
and patent expiries.
-CONSUMER JV: The FTSE 100-listed drug maker confirmed it was
targeting 2022 as the separation date for its consumer-health
business. Chief Executive Emma Walmsley said in a call that the
timeline for the joint venture with Pfizer Inc. (PFE) was
unchanged. She also said an eventual spinoff continued to be
expected.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com;
@carlomartu
(END) Dow Jones Newswires
February 05, 2020 09:43 ET (14:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024